GleamWall
中文EN

VRTX VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations · Nasdaq · SEC CIK 875320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.5%
TTM net income YoY8.2%
TTM EPS YoY9.4%
Revenue 3-yr CAGR10.3%
Net income 3-yr CAGR4.6%

Margins

Gross margin85.5%
Operating margin33.2%
Net margin30.7%
FCF margin24.7%
EBITDA margin35.1%

Returns

ROE20.8%
ROA13.8%
ROIC (approx.)21.9%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets36.1%
Debt / equity0.22x
Current ratio2.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio1.0%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$12.00B$11.02B
Cost of revenue$1.65B$1.53B
Gross profit$10.35B$9.49B
R&D expense$3.91B$3.63B
SG&A expense$1.75B$1.46B
Operating income$4.17B-$232.90M
Interest expense$13.30M$30.60M
Pretax income$4.64B$248.50M
Income tax$690.00M$784.10M
Net income$3.95B-$535.60M
EBITDA$4.38B-$25.70M
EPS (basic)15.46-2.08
EPS (diluted)15.32-2.08
Weighted avg. shares (diluted)258.00M257.90M
Balance sheet
Cash & equivalents$5.08B$4.57B
Short-term investments$1.52B$1.55B
Receivables$2.05B$1.61B
Inventory$1.69B$1.21B
Current assets$11.20B$9.60B
PP&E, net$1.52B$1.23B
Goodwill$1.09B$1.09B
Intangibles$424.20M$825.90M
Total assets$25.64B$22.53B
Current liabilities$3.86B$3.56B
Short-term debt$0—
Long-term debt$0—
Total debt$0—
Total liabilities$6.98B$6.12B
Shareholders' equity$18.67B$16.41B
Net debt-$5.08B—
Shares outstanding253.99M256.94M
Cash flow statement
Operating cash flow$3.63B-$492.60M
Capital expenditure$437.60M$297.70M
Free cash flow$3.19B-$790.30M
Investing cash flow-$945.40M-$3.77B
Financing cash flow-$2.26B-$1.49B
Depreciation & amortization$209.80M$207.20M
Stock-based compensation$685.90M$698.50M
Share buybacks$2.02B$1.18B

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.